Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Full Approval To VITRAKVI for NTRK Fusion Solid Tumors
Details : Vitrakvi (larotrectinib sulfate) is an inhibitor of the TRKA, TRKB, and TRKC. It is approved for the treatment of adult and pediatric patients with ntrk gene fusion-positive solid tumors.
Product Name : Vitrakvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
